Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
IntroductionEfgartigimod has been approved for the treatment of acetylcholine receptor antibodies-positive generalized myasthenia gravis (AChR-Ab+gMG), but its efficacy in patients with ocular myasthenia gravis (OMG) is not known.Case presentationWe describe 2 cases of patients with AChR-Ab+ OMG who...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1497398/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|